Transient Expression Platform
OmniCHO™
Fast, high-fidelity transient expression built on the SUPERCELL™ lineage. Enables early candidate evaluation with CQAs aligned to downstream development.
Technology foundation
SUPERCELL™
CHO-K1 lineage
-
Proven CHO-K1 foundation
Built on the KAO / Puck / Chasin original CHO-K1 cell line – trusted across biopharma.
-
Directed evolution
SUPERCELL™ was developed via phenotypic selection to improve folding, redox balance, and cell stability.
-
Proprietary Evolution Path
Celltheon owns this cell line and continues to evolve it through selection and engineering, ensuring it remains the leading CHO-K1 cell line.
-
Why lineage matters
Within the proven CHO-K1 ecosystem, SUPERCELL™ delivers higher expression, stable CQAs, and predictable scale-up.
what we offer
Biopharma services built
for speed, quality, and scale
Platform performance
SUPERCELL™ — engineered for consistent quality, predictable scale-up, and high productivity
SUPERCELL™ is a next-generation CHO-K1 cell line optimized for consistent product quality, efficient scale-up, and high productivity.
-
Product quality
High monomer content and tunable CQAs based on a proven CHO-K1 lineage.
-
Easy Scale-up
Fast growth, no clumping, and low oxygen demand for predictable scale-up.
-
High Productivity
High cell densities and titers, including difficult-to-express proteins.
-
Long-term stability
Stable metabolism and performance across extended culture generations.
Data overview
Protein expression performance
Difficult Molecules, Exceptional Titers
SUPERCELL™ delivers reliable pool titers of 6–14 g/L across challenging protein formats, including bispecifics and scFvs. This reduces screening effort and accelerates candidate selection.
Molecule format
Typical pool titers
Fc-fusion
13.79g/L
Lipoprotein
10.69g/L
4-Chain Bispecific
11.01g/L
Nanobody fusion
11.41g/L
Braikinumab
10.41g/L
Adalimumab
9.36g/L
Trastuzumab
8.84g/L
Seribantumab
8.39g/L
Lenzilumab
7.8g/L
Who SUPERCELL™ is built for
Designed for difficult molecules, complex formats, and scale-up certainty
Designed for molecules that fail on standard CHO platforms due to folding, stability, or secretion limitations — enabling expression where others stall.
-
Difficult-to-express proteins
Enables expression of molecules that fail on standard CHO platforms due to folding, stability, or secretion constraints.
-
Complex antibody formats
Optimized for complex modalities like scFvs, bispecifics, and Fc-fusions where quality and titers are hard to sustain.
-
Programs with scale-up risk
Ensures early expression success translates reliably from plates to bioreactors without re-optimization or drift.
-
Predictable CQAs required
Provides consistent control of critical quality attributes across development stages to reduce regulatory risk and downstream surprises.
